dr donna h ryan glp 1 GLP-1 rec agonists have evolved over the past 20+ years as game-changers for type 2 diabetes to highly effective medications for the treatment of obesity by targeting the neurometabolic pathophysiology of obesity Obesity Medicine | Clinical Topics
Description
To Use: Select an area of skin
At the same time, payer policies often require discontinuation of GLP-1 therapy when a patients BMI drops below a set threshold, inadvertently triggering a frustrating cycle of weight loss and regainthe so-called yo-yo effect. This not only impacts ongoing adherence and persistence but also undermines the long-term cost-effectiveness of these therapies for healthcare systems
P=0.001] and whole-body bone mineral density [MD0.02 kg/m2 (95% CI,0.04 to0.00)
Taking Ozempic or Mounjaro in La Quinta
